RxDoctor Payments Data

Sheila Weaver, DO

Pulmonary Disease · Philadelphia, PANPI 1831187970

Payments from drug & device makers

$49,638in general payments, 2019–2025

Across 53 payments — averaging $936.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • United Therapeutics Corporation$32K
  • Actelion Pharmaceuticals US, Inc.$7K
  • Janssen Research & Development, LLC$6K
  • Sumitomo Pharma America, Inc.$4K
  • Harmony Biosciences LLC$563
  • Inspire Medical Systems, Inc.$197
  • plus $212 from 4 others

What the payments were for

  • Food & beverage$79276%
  • Education$24724%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$49,638 in reported general payments places this provider in the 85th percentile of 703 pulmonary disease providers in Pennsylvania.

See all pulmonary disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$91,744
Medicare patients
329
Services billed
938

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Tyvaso DpiTreprostinil24$576,719
OpsumitMacitentan44$559,850
AdempasRiociguat44$551,851
UptraviSelexipag27$512,814
Orenitram ErTreprostinil Diolamine20$406,988
OfevNintedanib Esylate31$348,107
WinrevairSotatercept-Csrk13$236,508
Trelegy ElliptaFluticasone/Umeclidin/Vilanter127$101,822
Ambrisentan30$75,230
Dupixent PenDupilumab15$51,583
Breo ElliptaFluticasone/Vilanterol59$32,870
Spiriva RespimatTiotropium Bromide37$22,459
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr27$12,607
Combivent RespimatIpratropium/Albuterol Sulfate17$10,068
Breztri AerosphereBudesonide/Glycopyr/Formoterol14$8,793

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi$7,267$1,072,66471 claims
MerckWinrevair$62$236,50813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 703 pulmonary disease providers in Pennsylvania.

Other pulmonary disease in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →